Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058887 | 1.00 | NR4A2 (0.53) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL16034830 | 0.88 | NR4A2 (0.48) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL21857614 | 0.86 | NR4A2 (0.53) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL15766202 | 0.85 | NR4A2 (0.46) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL10153310 | 0.83 | NR4A2 (0.47) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL30017691 | 0.80 | NR4A2 (0.53) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL155514 | 0.80 | NR4A2 (0.53) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL4577829 | 0.80 | NR4A2 (0.56) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL29773857 | 0.80 | NR4A2 (0.56) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL5502679 | 0.78 | KDM4E (0.55) | CYP1A2CYP2C9CYP2C19HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105779-A | Preparation method of 5-bromo-2-formylbenzoic acid methyl ester | 河南师范大学 | 2023-11-24 | — | — | CN | claimed |
| CN-113527313-B | Preparation method and application of water-soluble supermolecule organic cage-shaped compound for detecting pyridinium substances in water | 浙江浙能技术研究院有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-113527313-A | Preparation method and application of water-soluble supermolecule organic cage-shaped compound for detecting pyridinium substances in water | 浙江浙能技术研究院有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4587127-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059806-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-7566727-B2 | 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor | ASTRAZENECA AB | 2009-07-28 | — | — | US | disclosed |
| US-20070213342-A1 | Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | US | disclosed |
| EP-1737854-A1 | NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100351-A1 | NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | NR4A2 2992/4885ALDH1A1 2481/4885GAA 579/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | NR4A2 2024/4885ALDH1A1 2571/4885GAA 9/4885 |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | NR4A2 99/4885ALDH1A1 2602/4885GAA 3864/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | NR4A2 99/4885ALDH1A1 2602/4885GAA 3864/4885 |
| US-20070213342-A1 | Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor | CHRNA1, CHRNA7, CHRNE | NR4A2 286/4885ALDH1A1 481/4885GAA 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.